Detail of "19735-89-8"

Reference

Pyrazole derivatives and their use as stabilizers for organic materials

Pyrazole derivatives and their use as stabilizers for organic materials. Aver, Lajos; Hofer, Kurt; Preiswerk, Martin (Sandoz Ltd., Switz.). Brit. GB 1474282 18 May 1977, 4 pp., Addn. to Brit. 1,474,281. (English). (United Kingdom). CODEN: BRXXAA. CLASS: IC: C07D231-22. APPLICATION: GB 74-29525 3 Jul 1974. DOCUMENT TYPE: Patent CA Section: 36 (Plastics Manufacture and Processing) Section cross-reference(s): 28 The Ni complex I [56557-00-7], prepd. from 1-phenyl-3-methylpyrazolone [19735-89-8], capryl chloride [112-13-0], and Ni acetate, stabilizes polymers and synthetic fibers against the effects of heat, oxidn., and UV light.

Metabolic disposition of antipyrine in patients with lung cancer

Metabolic disposition of antipyrine in patients with lung cancer. Tschanz, Christian; Hignite, Charles E.; Huffman, David H.; Azarnoff, Daniel L. (Coll. Health Sci., Univ. Kansas Med. Cent., Kansas City, Kans., USA). Cancer Res., 37(11), 3881-6 (English) 1977. CODEN: CNREA8. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacodynamics) The metab. of antipyrine (I) [60-80-0] (10 mg/kg, i.v.) was studied in 9 patients with cancer of the lung and in a cancer-free control group matched for age, sex, drug intake, and smoking and drinking history. The mean plasma clearance of I was 0.0475 L/kg/h in the tumor group and 0.0557 L/kg/h in the control group. The plasma elimination half-life was longer in the group with tumors (9.5 h) compared to the control group (7.7 h), but the difference was not statistically significant. There was no difference between the groups in the excretion of 2 major I metabolies, 4-hydroxyantipyrine [1672-63-5] and N-demethylantipyrine [19735-89-8], in a 48-h urine sample. Thus, the presence of lung cancer in humans does not significantly alter I elimination.